140 related articles for article (PubMed ID: 10826740)
1. Analysis of the long-term efficacy and selectivity of immunoadsorption columns for low density lipoprotein apheresis.
Jovin IS; Taborski U; Müller-Berghaus G
ASAIO J; 2000; 46(3):298-300. PubMed ID: 10826740
[TBL] [Abstract][Full Text] [Related]
2. Three-year treatment of familial heterozygous hypercholesterolemia by extracorporeal low-density lipoprotein immunoadsorption with polyclonal apolipoprotein B antibodies.
Richter WO; Jacob BG; Ritter MM; Sühler K; Vierneisel K; Schwandt P
Metabolism; 1993 Jul; 42(7):888-94. PubMed ID: 8345799
[TBL] [Abstract][Full Text] [Related]
3. Extracorporal low-density lipoprotein elimination by immunoadsorption.
Ritter MM; Parhofer KG
Ther Apher Dial; 2003 Jun; 7(3):370-2. PubMed ID: 12924615
[TBL] [Abstract][Full Text] [Related]
4. Effects of LDL apheresis on restenosis after angioplasty.
Kanemitsu S; Tekekoshi N; Murakami E
Chem Phys Lipids; 1994 Jan; 67-68():339-43. PubMed ID: 8187232
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of different low-density lipoprotein apheresis methods.
Parhofer KG; Geiss HC; Schwandt P
Ther Apher; 2000 Oct; 4(5):382-5. PubMed ID: 11111821
[TBL] [Abstract][Full Text] [Related]
6. Direct adsorption of low-density lipoprotein and lipoprotein(a) from whole blood: results of the first clinical long-term multicenter study using DALI apheresis.
Bosch T; Lennertz A; Schenzle D; Dräger J;
J Clin Apher; 2002; 17(4):161-9. PubMed ID: 12494408
[TBL] [Abstract][Full Text] [Related]
7. Low density lipoprotein apheresis in treatment of hyperlipidemia: experience with four different technologies.
Bambauer R; Schiel R; Latza R
Ther Apher; 2000 Jun; 4(3):213-7. PubMed ID: 10910023
[TBL] [Abstract][Full Text] [Related]
8. Low-density lipoprotein (LDL) oxidizability before and after LDL apheresis.
Donner MG; Parhofer KG; Richter WO; Schwandt P
Metabolism; 1999 Jul; 48(7):881-6. PubMed ID: 10421230
[TBL] [Abstract][Full Text] [Related]
9. Composition and immunoreactivity of serum low density lipoproteins (LDL) before and after LDL-apheresis on dextran sulfate-cellulose columns.
Gandjini H; Gambert P; Athias A; Mousson C; Rifle G; Lallemant C
Transfus Sci; 1994 Sep; 15(3):289-97. PubMed ID: 10155547
[TBL] [Abstract][Full Text] [Related]
10. [The choice of the optimal regimen for apheresis of the low-density lipoproteins in patients with familial hypercholesterolemia by using mathematical modelling].
Iarovaia EB; Rostapshova TV; Susekov AV; Kukharchuk VV
Kardiologiia; 1993; 33(10):50-4, 6. PubMed ID: 8139174
[TBL] [Abstract][Full Text] [Related]
11. Lipid reductions by low-density lipoprotein apheresis: a comparison of three systems.
Jovin IS; Taborski U; Stehr A; Müller-Berghaus G
Metabolism; 2000 Nov; 49(11):1431-3. PubMed ID: 11092506
[TBL] [Abstract][Full Text] [Related]
12. Changes in serum afamin and vitamin E levels after selective LDL apheresis.
Varga VE; Lőrincz H; Szentpéteri A; Juhász L; Seres I; Paragh G; Balla J; Paragh G; Harangi M
J Clin Apher; 2018 Oct; 33(5):569-575. PubMed ID: 30247793
[TBL] [Abstract][Full Text] [Related]
13. Long-term therapeutic efficacy of lipoprotein apheresis on circulating oxidative stress parameters--A comparison of two different apheresis techniques.
Kopprasch S; Bornstein SR; Bergmann S; Graessler J; Julius U
Atheroscler Suppl; 2015 May; 18():80-4. PubMed ID: 25936309
[TBL] [Abstract][Full Text] [Related]
14. Low-density lipoprotein apheresis using the Liposorber dextran sulfate cellulose system for patients with hypercholesterolemia refractory to medical therapy.
Gordon BR; Saal SD
J Clin Apher; 1996; 11(3):128-31. PubMed ID: 8915816
[TBL] [Abstract][Full Text] [Related]
15. Removal of plasma mature and furin-cleaved proprotein convertase subtilisin/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9.
Hori M; Ishihara M; Yuasa Y; Makino H; Yanagi K; Tamanaha T; Kishimoto I; Kujiraoka T; Hattori H; Harada-Shiba M
J Clin Endocrinol Metab; 2015 Jan; 100(1):E41-9. PubMed ID: 25313916
[TBL] [Abstract][Full Text] [Related]
16. Development of immunosorbents for apoB-containing lipoproteins apheresis.
Pokrovsky SN; Sussekov AV; Adamova IY; Afanasieva OI; Benevolenskaya GF; Konovalov GA; Kukharchuk VV
Artif Organs; 1995 Jun; 19(6):500-5. PubMed ID: 8526788
[TBL] [Abstract][Full Text] [Related]
17. A new low density lipoprotein apheresis system using two dextran sulfate cellulose columns in an automated column regenerating unit (LDL continuous apheresis).
Mabuchi H; Michishita I; Takeda M; Fujita H; Koizumi J; Takeda R; Takada S; Oonishi M
Atherosclerosis; 1987 Nov; 68(1-2):19-25. PubMed ID: 2446636
[TBL] [Abstract][Full Text] [Related]
18. Current status of low density lipoprotein-apheresis for the therapy of severe hyperlipidemia.
Gordon BR; Saal SD
Curr Opin Lipidol; 1996 Dec; 7(6):381-4. PubMed ID: 9117142
[TBL] [Abstract][Full Text] [Related]
19. Selective removal of apolipoprotein B-containing serum lipoproteins from blood plasma.
Stoffel W; Demant T
Proc Natl Acad Sci U S A; 1981 Jan; 78(1):611-5. PubMed ID: 7017720
[TBL] [Abstract][Full Text] [Related]
20. Humoral immune response following extracorporeal immunoadsorption therapy of patients with hypercholesterolemia.
Gordon BR; Sloan BJ; Parker TS; Saal SD; Levine DM; Rubin AL
Transfusion; 1990 May; 30(4):327-32. PubMed ID: 2190366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
